Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

CXCR2‐modified CAR‐T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma

(2020) Guangna Liu et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials

(2020) Donghua Shi et al.   CLINICAL CANCER RESEARCH

Hepatic Regulator of G protein Signaling 5 Ameliorates NAFLD by Suppressing TAK1-JNK/p38 Signaling

(2020) Junyong Wang et al.   HEPATOLOGY

The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview

(2020) Niels Schaft   Cancers

CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth

(2020) Xiaodong Zhuang et al.   JCI Insight

Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice

(2019) Yushu Joy Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia-induced VISTA promotes the suppressive function of myeloid- derived suppressor cells in the tumor microenvironment

(2019) Jie Deng et al.   Cancer Immunology Research

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

(2019) Rachel Grosser et al.   CANCER CELL

TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo

(2019) Kristina Petrovic et al.   PLoS One

Cancer Metabolism: Current Understanding and Therapies

(2018) Jessica L. Counihan et al.   CHEMICAL REVIEWS

A guide to chemokines and their receptors

(2018) Catherine E. Hughes et al.   FEBS Journal

Targeting fibroblast activation protein in cancer ndash Prospects and caveats

(2018) Aleksi Sedo   Frontiers in Bioscience-Landmark

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

(2018) Gregory L. Beatty et al.   GASTROENTEROLOGY

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

(2018) Keishi Adachi et al.   NATURE BIOTECHNOLOGY

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

(2018) Sarwish Rafiq et al.   NATURE BIOTECHNOLOGY

CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions

(2018) Wanghong Hu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The success and the challenge of all-trans retinoic acid in the treatment of cancer

(2018) Xiaoling Ni et al.   CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION

Targeting both tumour-associated CXCR2+neutrophils and CCR2+macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

(2017) Timothy M Nywening et al.   GUT

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

(2017) Frederick Arce Vargas et al.   IMMUNITY

Oxygen availability and metabolic reprogramming in cancer

(2017) Hong Xie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients

(2017) Richard P. Tobin et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers

(2017) Chengcheng Zhang et al.   MOLECULAR THERAPY

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer

(2017) Somala Mohammed et al.   MOLECULAR THERAPY

Immunotherapy: Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers

(2017) Vinay Prasad   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9

(2017) Jiangtao Ren et al.   Protein & Cell

Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy

(2017) Anne-Sophie Gautron et al.   Molecular Therapy-Nucleic Acids

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

(2017) Nabil Ahmed et al.   JAMA Oncology

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

(2016) Elise A. Chong et al.   BLOOD

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

(2016) Xiaojun Liu et al.   CANCER RESEARCH

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

(2016) Jiangtao Ren et al.   CLINICAL CANCER RESEARCH

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status

(2016) Yosra Messai et al.   EUROPEAN UROLOGY

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

(2016) Frank A. Schildberg et al.   IMMUNITY

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

(2016) Timothy M Nywening et al.   LANCET ONCOLOGY

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

(2016) Tessa Gargett et al.   MOLECULAR THERAPY

Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer

(2016) Caroline Wigerup et al.   PHARMACOLOGY & THERAPEUTICS

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

(2016) Richard P. Junghans et al.   PROSTATE

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

(2016) Eloah Rabello Suarez et al.   Oncotarget

Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization

(2016) K. Newick et al.   Cancer Immunology Research

Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice

(2016) Ava Vila-Leahey et al.   OncoImmunology

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

(2015) Soranobu Ninomiya et al.   BLOOD

Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

(2015) Rachel A. Burga et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Role of Stroma in Tumor Development

(2015) Zena Werb et al.   CANCER JOURNAL

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells

(2015) A. Lo et al.   CANCER RESEARCH

PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

(2015) Nisha Nagarsheth et al.   CANCER RESEARCH

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

The Evolution of T-cell Therapies for Solid Malignancies

(2015) K. Fousek et al.   CLINICAL CANCER RESEARCH

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

(2015) S. C. Katz et al.   CLINICAL CANCER RESEARCH

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages

(2015) Takanori Kitamura et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity

(2015) Maarten A. Ligtenberg et al.   JOURNAL OF IMMUNOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes

(2015) Ignazio Caruana et al.   NATURE MEDICINE

HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells

(2015) Huimin Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model

(2015) L. Wang et al.   Cancer Immunology Research

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis

(2015) Emilia Andersson et al.   OncoImmunology

CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy

(2014) D. R. Soto-Pantoja et al.   CANCER RESEARCH

Trafficking of T Cells into Tumors

(2014) C. Y. Slaney et al.   CANCER RESEARCH

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

(2014) Yannick Bulliard et al.   IMMUNOLOGY AND CELL BIOLOGY

Therapeutic use of anti-CTLA-4 antibodies

(2014) C. U. Blank et al.   INTERNATIONAL IMMUNOLOGY

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor

(2014) Ann M Leen et al.   MOLECULAR THERAPY

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

(2014) Laura Bonapace et al.   NATURE

CXC chemokines and chemokine receptors in gastric cancer: From basic findings towards therapeutic targeting

(2014) Hyo Jin Lee   WORLD JOURNAL OF GASTROENTEROLOGY

T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression

(2014) S. P. Santoro et al.   Cancer Immunology Research

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells

(2013) I. B. Barsoum et al.   CANCER RESEARCH

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency

(2013) W Wang et al.   GENE THERAPY

Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery

(2013) Xinping Fu et al.   INTERNATIONAL JOURNAL OF CANCER

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia

(2013) Edward W. Roberts et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

(2013) Eric Tran et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells

(2013) Petra C Schuberth et al.   Journal of Translational Medicine

Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma

(2013) Sunitha Kakarla et al.   MOLECULAR THERAPY

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia

(2013) J. Baginska et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans

(2013) D. Sugiyama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

(2013) G. L. Beatty et al.   Cancer Immunology Research

Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity

(2013) L.-C. S. Wang et al.   Cancer Immunology Research

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

(2012) D Lorusso et al.   BRITISH JOURNAL OF CANCER

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

(2012) L Zhang et al.   GENE THERAPY

Targeting TNF-  to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

(2012) A. Calcinotto et al.   JOURNAL OF IMMUNOLOGY

T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy

(2012) Jon G Quatromoni et al.   Journal of Translational Medicine

Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma

(2012) Soranobu Ninomiya et al.   LEUKEMIA & LYMPHOMA

Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells

(2012) Yisheng Zheng et al.   MOLECULAR IMMUNOLOGY

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor-targeted TNF  stabilizes tumor vessels and enhances active immunotherapy

(2012) A. Johansson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autocrine CCL5 Signaling Promotes Invasion and Migration of CD133+Ovarian Cancer Stem-Like Cells via NF-κB-Mediated MMP-9 Upregulation

(2012) Haixia Long et al.   STEM CELLS

HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy

(2012) Wei-Hua Yan   Endocrine Metabolic & Immune Disorders-Drug Targets

Won’t you come on in? How to favor lymphocyte infiltration in tumors

(2012) Matteo Bellone et al.   OncoImmunology

Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy

(2011) E. Dondossola et al.   CANCER RESEARCH

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

(2011) Barbara Molon et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Hypoxia-Dependent Inhibition of Tumor Cell Susceptibility to CTL-Mediated Lysis Involves NANOG Induction in Target Cells

(2011) Meriem Hasmim et al.   JOURNAL OF IMMUNOLOGY

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

(2011) Bin-Zhi Qian et al.   NATURE

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

(2011) Andrea Facciabene et al.   NATURE

Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP

(2010) Soranobu Ninomiya et al.   ANNALS OF HEMATOLOGY

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

Chemokines as mediators of tumor angiogenesis and neovascularization

(2010) Ellen C. Keeley et al.   EXPERIMENTAL CELL RESEARCH

IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion

(2010) V. Gocheva et al.   GENES & DEVELOPMENT

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

(2010) Dhanalakshmi Chinnasamy et al.   JOURNAL OF CLINICAL INVESTIGATION

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: An unexpected prognostic significance?

(2010) Leos Kren et al.   NEUROPATHOLOGY

Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21

(2010) J. D. Shields et al.   SCIENCE

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD

Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor  -Insensitive CD8+ T Cells

(2009) L. Wang et al.   CLINICAL CANCER RESEARCH

Therapeutic targeting of myeloid-derived suppressor cells

(2009) Stefano Ugel et al.   CURRENT OPINION IN PHARMACOLOGY

RGS5, a Hypoxia-inducible Apoptotic Stimulator in Endothelial Cells

(2009) Yi Jin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells

(2009) E. M. Hanson et al.   JOURNAL OF IMMUNOLOGY

Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood

(2008) Camilla Jandus et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4

(2008) M Todaro et al.   CELL DEATH AND DIFFERENTIATION

Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-?? Receptor

(2008) Aaron E. Foster et al.   JOURNAL OF IMMUNOTHERAPY

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

(2008) Juliana Hamzah et al.   NATURE

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

(2007) Ronald J Buckanovich et al.   NATURE MEDICINE